

REQUEST FOR PROPOSAL	LSU	BID DUE DATE AND TIME
BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL & MECHANICAL COLLEGE		06/09/2020 02:00 PM CT

SOLICITATION RFQ-0000001181 SUPPLIER # SUPPLIER NAME AND ADDRESS <div data-bbox="175 394 789 604" style="border: 1px solid black; height: 100px; width: 100%;"></div>	RETURN BID TO Louisiana State University and Agricultural and Mechanical College Procurement 213 Thomas Boyd Hall Baton Rouge, LA 70803 Buyer Jene Troxclair Ledet Buyer Phone Buyer Email jeneledet@lsu.edu Issue Date 05/04/2020
---	--

TITLE: Pharmacy Benefit Management Services

ADDENDUM 02: Notice is given to all parties that this Solicitation is amended by the University as stated herein. This Addendum is hereby made an official part of this solicitation. Written inquiries have been received and responses are offered per the attached. Also see attached revised Exhibit B and the Preferred Formulary Document referenced in response to question 13.

This area left intentionally blank.

Addendum 02
RFQ-0000001181
Vendor Inquires and responses

Q1) Given the COVID-19 guidance and the move toward electronic submission, does the University still want 10 hard copies?

R1) Delete all reference to proposals being delivered by hand or courier service or mailed through the U.S. Postal Services and the number of copies required and replace with “bids must be submitted electronically to LSU Procurement Services until further notice. Bids must be emailed to lsubids@lsu.edu (***This email address should be used for bid submissions only***). ***An original and redacted copy (if applicable) must be submitted electronically.*** When submitting electronically, the RFQ number and solicitation title should be listed in the subject line of the email. If you have submitted a bid through USPS, FedEx, UPS or another mail carrier, it is your responsibility to send an additional copy electronically. Neither the physical bids nor late bids will be accepted. Any supplier who would like to view the opening of this bid can access the following link: <https://lsu.zoom.us/meeting/register/u5Yoc-mtpjwic3qMBbUv2mGXg3EyfFeWww>. The link will be live at 2:00 PM CST on the date of bid opening and will provide live audio and video access to this bid opening.”

Q2) The RFQ states that the Plan is a self-funded health insurance plan offered to employees and independents of LSU and certain other Louisiana governmental agencies. Based on this statement, would you please confirm the total lives covered for this opportunity?

R2) Membership as of May 2020 is 17,972 lives (9130 employees and 8842 dependents).

Q3) You indicate that the vendor will need have 3 years’ experience with 3 different university systems with 10,000 lives. While we have a vast amount of experience with health plans (with over 750,000 lives), smaller universities, and the Louisiana Health Cooperative (now expired ACA-created CO-OP), we do not meet this exact requirement. Please let us know if this disqualifies us from participation.

R3) Section 4.5 shall be replaced with “Respondent must provide any available evidence to demonstrate its ability to address the unique needs of LSU. Respondent must provide evidence of at least three years of experience providing PBM services. Respondent shall provide three references with their proposal (including name, title, client name, address, email address, telephone number and number of enrolled members). Note that LSU may take past business experience with respondent Supplier into consideration as a reference in scoring of this section.”

Q4) Due to the circumstances regarding COVID-19, there are challenges with hard copy production. Would you grant vendors permission to submit this RFP electronically?

R4) Delete all reference to proposals being delivered by hand or courier service or mailed through the U.S. Postal Services and the number of copies required and replace with “bids must be submitted

electronically to LSU Procurement Services until further notice. Bids must be emailed to lsubids@lsu.edu (***This email address should be used for bid submissions only***). ***An original and redacted copy (if applicable) must be submitted electronically.*** When submitting electronically, the RFQ number and solicitation title should be listed in the subject line of the email. If you have submitted a bid through USPS, FedEx, UPS or another mail carrier, it is your responsibility to send an additional copy electronically. Neither the physical bids nor late bids will be accepted. Any supplier who would like to view the opening of this bid can access the following link: <https://lsu.zoom.us/meeting/register/u5Yoc-mtpjwic3qMBbUv2mGXg3EyfFeWww>. The link will be live at 2:00 PM CST on the date of bid opening and will provide live audio and video access to this bid opening.”

Q5) Will LSU permit questions after the exhibits and claims data have been received?

R5) Per Addendum 01, the Schedule of Events was revised, and the deadline for receiving written inquires was extended to 5/22/20.

Q6) We understand that the fees charged to Louisiana State University, as well as the total amount spent on the pharmacy benefit, must be made available to the public upon request, however, please confirm that bidders are permitted to mark individual minimum guarantees of financial performance (such as yearly minimum ingredient cost discount guarantees), which constitute trade secret information of bidder under applicable law, as confidential and proprietary. (Section 1.6)

R6) The designation of certain information as trade secrets and/or privileged or confidential proprietary information shall only apply if protections are claimed by the Respondent at the time of submission of its Technical Proposal in accordance with Section 1.6 - Confidential Information, Trade Secrets, and Proprietary Information.

Q7) The RFP indicates that the vendor will need to have 3 years’ experience with 3 different university systems with 10,000 lives. If this is an explicit requirement, **please confirm this disqualifies the vendor from participation.**

R7) Section 4.5 shall be replaced with “Respondent must provide any available evidence to demonstrate its ability to address the unique needs of LSU. Respondent must provide evidence of at least three years of experience providing PBM services. Respondent shall provide three references with their proposal (including name, title, client name, address, email address, telephone number and number of enrolled members). Note that LSU may take past business experience with respondent Supplier into consideration as a reference in scoring of this section.”

Q8) Is your current specialty program an exclusive arrangement or open to all pharmacies?

R8) Exclusive.

Q9) Is your Retail Pharmacy Network considered Broad? Are there any chain pharmacies excluded from the retail pharmacy network? If so, which chains?

R9) Yes, the Retail Pharmacy Network is considered broad. No retail pharmacy is excluded.

Q10) Is LSU looking for PBM vendors to provide a repricing analysis for the claims file?

R10) No, Respondents are to supply the requested information in the RFP.

Q11) Please confirm there are no commission to be built into our offer.

R11) Correct.

Q12) Please provide detailed information on any clinical programs that are currently being utilized by LSU.

R12) Below are programs that LSU is currently utilizing:

Prior Authorization

The incumbent's Prior Authorization (PA) program includes recommended edits for medications that have dangerous side effects, can be harmful when combined with other drugs, should be used only for certain health conditions, are often misused or abused, or less expensive drugs might work better. PA edits are intended to prevent improper prescribing practices, ensuring members are treated with the most clinically and cost-effective drug therapies available. A licensed, qualified pharmacist will conduct the review of the prior authorization requested for a member's medication.

Quantity Level Limits/Dose Optimization

To ensure medications are dispensed in quantities that are clinically appropriate for the plan's benefit design, our quantity level limit program promotes both clinical and economic outcomes based on appropriate drug dosing. Our quantity limits are based on prescribing guidelines and our Pharmacy and Therapeutics Committee review to ensure medication use is consistent with approved dosing regimens to optimize patient safety.

STEP Therapy Program

With over 550 possible custom criteria, our STEP care requires a member use a clinically recognized first-line drug before approval of a more complex and often more expensive second-line drug is authorized. Step therapy requirements ensure an established and cost-effective therapy is utilized prior to progressing to other therapies. If the required therapeutic benefit is not achieved by use of the first-line drug, the prescriber may request use of a second-line medication.

Rx Assist

Our Rx Assist program targets select specialty medications to capture manufacturer copay coupon amounts and applies the savings to the Plan. Members are provided with a wide range of support tools including refill reminders, educational outreach and follow-up from registered incumbent pharmacists.

With incumbent's Rx Assist program, members have access to:

- A personal Patient Care Coordinator to keep them motivated to stay on track with their treatment plan.
- Timely reminders to help with medicine, prescription refills, and doctors' appointments.
- Educational support – Patient Care Coordinators get to know members on a personal level to best support their individual needs.
- Regularly scheduled, integrated touch points determined by member's individual preferences.

Opioid Drug Management Program

Incumbent offers various ways to manage opioids, including:

- Restrictive Refill Limitations: Opioid refills will be denied if a member attempts to fill their prescription prior to exhausting 90% of their medication supply from their last fill, versus the standard 70% established for other medications.
- Quantity Level Limits: Short-acting opioids have limits established to prevent a member from receiving 4000 mg of acetaminophen a day (the maximum daily dose), or an opioid dose of 90 mg Morphine Equivalent Dose daily (MED). MED is used to quantify how much opioid someone is receiving by converting morphine and/or other opioids such as oxycodone and hydrocodone into the same calculation. A MED of 90 mg has been established by the Centers for Disease Control (CDC) as a threshold, at which if a patient's dose is increased above 90 mg MED per day without substantial improvement in function and pain, a consult should be sought by a pain specialist. This guideline is regarded as one of the standards of opioid management.

Long-acting opioid products have limits established based on regular dosing intervals (e.g. Oxycontin® should not be taken more than every 12 hours) or a MED of 90 mg, whichever comes first.

- Restrictive Day Supply Limits: All short-acting opioids require prior authorization after 7 days of therapy. This applies to the entire medication class and is not agent specific, meaning if an individual starts using hydrocodone/APAP and switches to oxycodone/APAP, both fills contribute to the 7-day period limit rather than re-starting. This limit applies to a period of 30 days, meaning after receiving 7 days of therapy within 30 days, a member may only receive additional therapy after the 30 day period. All long-acting opioids will be limited to a 30-day supply and will require prior authorization to help guide appropriate duration of therapy and agent selection.

Q13) Please confirm if your current formulary contains any exclusions.

R13) Formulary exclusions are identified in the Preferred Formulary Document provided in this Addendum 02, and in Exhibit N: Summary Plan Document.

Q14) Please confirm the total employee and lives count. Additionally, please confirm which of those lives are RDS lives, and if the RDS population is pre or post-65

R14) Membership as of May 2020 is 17,972 lives (9130 employees and 8842 dependents). The Retiree Drug Subsidy (RDS) Program was enacted in December 2003 to reimburse Plan Sponsors for a portion of their Qualifying Covered Retirees' costs for prescription drugs otherwise covered by Medicare Part D that are attributable to such drug costs between the applicable Cost Threshold and Cost Limit. Most retirees will be post 65 but there could be instances where someone would qualify pre-65. Approximately 726 retiree and dependents are post 65.

Q15) Please outline the expectations of the sample contract review. We are interpreting requirement 1.38 to be a redlining contract process; however, the sample contract does not include all of the outlined non-negotiable terms mentioned in 1.38. The sample agreement also does not include any contract definitions or other standard contractual components.

R15) The intent of the sample contract is to provide a general idea of what the final contract will look like. The sample contract has been revised and now includes all the non-negotiable terms. See attached revised Exhibit B. Per section 1.38, the Respondent needs to address the specific language in the sample agreement and submit their Proposal with any exceptions or exact agreement deviations that their firm wishes to negotiate. The terms for both of these documents may be negotiated as part of the negotiation process with the exception of Agreement provisions that are non-negotiable.

Q16) Please confirm if the Sample Board Resolution signature page is just a sample or if the vendors are required to sign.

R16) Respondents must provide a Board Resolution if they are not utilizing the Sample provided in Exhibit E – Sample Board Resolution or Signature Authority.

Q17) In light of COVID-19, will LSU allow vendors to submit the bid electronically rather than hard copies?

R17) Delete all reference to proposals being delivered by hand or courier service or mailed through the U.S. Postal Services and the number of copies required and replace with “bids must be submitted electronically to LSU Procurement Services until further notice. Bids must be emailed to lsubids@lsu.edu (***This email address should be used for bid submissions only***). ***An original and redacted copy (if applicable) must be submitted electronically.*** When submitting electronically, the RFQ number and solicitation title should be listed in the subject line of the email. If you have submitted a bid through USPS, FedEx, UPS or another mail carrier, it is your responsibility to send an additional copy electronically. Neither the physical bids nor late bids will be accepted. Any supplier who would like to view the opening of this bid can access the following link: <https://lsu.zoom.us/j/7828122222>. The link will be live at 2:00 PM CST on the date of bid opening and will provide live audio and video access to this bid opening.”

Q18) Regarding 1.58: Supplier's personnel will comply with all security regulations in effect at the University's premises, and externally for materials and property belonging to the University or to the project. Supplier is responsible for promptly reporting to the University any known breach of security. please define "all security regulations"

R18) In light of COVID-19, all Supplier's will be required to follow any security regulations in effect any time a Supplier is on the University's premises.

Q19) What will be the expectation of the SPD that will be sent after the BAA is executed? Will vendors be expected to review and sign? Is there any intent behind the current SPD that has been provided in the RFP?

R19) There will not be an SPD sent after the BAA is executed. See Exhibit N for the Summary Plan Document. Vendors will not be expected to sign. The Summary Plan document outlines the function and protocols in which the LSU First Health plan operate. It also provides the current exclusions under the Pharmacy Benefit. Per the RFP, the respondent will work within the guidelines of the SPD.

Q20) Exhibit A - Certification Statement clearly states that it is to be "hand signed with blue ink". 1.5.1 Number of Response Copies states that (1) copy of the Proposal must contain original signatures. Due to COVID-19 precautions, will the wet signature requirement be reduced to an electronic signature?

R20) See response to question 1. We will accept electronic submittals and electronic signatures.

Q21) 1.32 Insurance Requirements - Is our COI to be supplied with our RFP response or after award/prior to go live?

R21) The Certificate of Insurance per the requirements as outlined in Section 1.32 - Insurance Requirements will be required prior to award.

Q22) Can an extension to the due date be provided?

R22) No.

Q23) Due to COVID-19, can the hard copy requirement be waived for the safety of our staff? If not, can the hard copy be sent after the electronic submission?

R23) Delete all reference to proposals being delivered by hand or courier service or mailed through the U.S. Postal Services and the number of copies required and replace with "bids must be submitted electronically to LSU Procurement Services until further notice. Bids must be emailed to lsubids@lsu.edu (***This email address should be used for bid submissions only***). ***An original and redacted copy (if applicable) must be submitted electronically.*** When submitting electronically, the

RFQ number and solicitation title should be listed in the subject line of the email. If you have submitted a bid through USPS, FedEx, UPS or another mail carrier, it is your responsibility to send an additional copy electronically. Neither the physical bids nor late bids will be accepted. Any supplier who would like to view the opening of this bid can access the following link: <https://lsu.zoom.us/meeting/register/u5Yoc-mtpjwic3qMBbUv2mGXg3EyfFeWww>. The link will be live at 2:00 PM CST on the date of bid opening and will provide live audio and video access to this bid opening.”

Q24) What is the anticipated membership for this opportunity?

R24) Membership as of May 2020 is 17,972 lives (9130 employees and 8842 dependents).

Q25) Is LSU interested in retaining an exclusionary formulary?

R25) Yes.

Q26) What is the count of members covered by the RFP?

R26) Membership as of May 2020 is 17,972 lives (9130 employees and 8842 dependents).

Q27) How many members are active versus retiree?

R27) Retirees total is approximately 2526 and active would be 15,446.

Q28) Is LSU experiencing any service issues with the current PBM?

R28) The current contract has no more renewal options. This solicitation is to ensure compliance with the Procurement Code.

Q29) Are there any consultants supporting the RFP process for LSU?

R29) Yes.

Q30) Is the WebTPA relationship also currently out to bid?

R30) No. See Section 1.1.3 for additional information.

Q31) Does LSU intend to continue the current benefit design going into the new contract term?

a. Would all 90 day prescriptions continue to be filled through the mail provider?

b. Would LSU consider a retail 90 day network?

R31) Yes, LSU intends to continue the current benefit design. a) LSU is open to a 90 day retail option under specific guidelines. b) Respondents can submit a proposal inclusive of a retail 90 day network option, but it will not be an evaluation factor during preliminary scoring. Proposals must be submitted according to original RFP requirements.

Q32) Along with other businesses, our company is currently operating on a temporary work from home policy, which may be the case for other respondents as well. Considering the unusual circumstances, will Louisiana State University consider changing the submission requirements regarding hard copies. Will it be possible to submit a reduced number of physical copies or to submit electronic-only responses?

R32) Delete all reference to proposals being delivered by hand or courier service or mailed through the U.S. Postal Services and the number of copies required and replace with "bids must be submitted electronically to LSU Procurement Services until further notice. Bids must be emailed to lsubids@lsu.edu (***This email address should be used for bid submissions only***). ***An original and redacted copy (if applicable) must be submitted electronically.*** When submitting electronically, the RFQ number and solicitation title should be listed in the subject line of the email. If you have submitted a bid through USPS, FedEx, UPS or another mail carrier, it is your responsibility to send an additional copy electronically. Neither the physical bids nor late bids will be accepted. Any supplier who would like to view the opening of this bid can access the following link: <https://lsu.zoom.us/meeting/register/u5Yoc-mtpjwic3qMBbUv2mGXg3EyfFeWww>. The link will be live at 2:00 PM CST on the date of bid opening and will provide live audio and video access to this bid opening."

Q33) Please confirm that the bid number for Louisiana State University and A&M College is 50001-1181.

R33) The solicitation number is RFQ-0000001181. The LaPac website will list the bid as 50001-1181.

Q34) Can you please confirm if the tier 4 specialty drugs within the data file are considered preferred or non-preferred medications?

R34) LSU doesn't use the categories "preferred" and "non-preferred". SRx drugs fall under tier 4. SRx=specialty drug

Q35) Within the reporting requirements, please outline what data LSU would expect to be captured in the administration of the pharmacy plan.

R35) Typical KPI- Key Performance Indicators such as Lag reports, claims totals divided by actives/pre-65 retirees/65+ retirees. Top drugs/therapeutic classes by # and by \$, etc. Benefit change modeling (i.e., how much would I save if I...? how many people would be affected if I...?), individual-level reports for CCC and bariatric, reports related to self-prescribers, COVID- and other disease-based reports.

Quarterly reports on spend, utilization, trend drivers, network access, top prescription count by classes, top Rx spend by classes, pending drug approvals and potential effect on plan.

There will be a number of data fields that will be required during audits and there will be regular ongoing file feeds to a data warehouse.

Q36) Please also confirm the NCPDP number for Freedom Pharmacy as we did not see it listed in the data file.

R36) Delete question 46 in Exhibit I: Additional Information.

REVISED EXHIBIT B - SAMPLE CONTRACT



BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE, PARISH OF EAST BATON ROUGE

Be it known, that on this DATE day of MONTH YEAR, the **Board of Supervisors of Louisiana State University and A&M College** (hereinafter sometimes referred to as the "University") and **Supplier's name address, city, state, etc.** (hereinafter sometimes referred to as "Supplier") do hereby enter into contract under the following terms and conditions.

SCOPE OF SERVICES: The Supplier shall provide Pharmacy Benefit Management services with a pass-through model for plan participants enrolled in the LSU First Health plan. **Proposals with traditional offers will not be evaluated.** LSU expects to pay competitive prescription wholesale drug prices, highly competitive administrative fees, and to have minimal disruption to the enrolled members of the LSU First plan. LSU further expects the Supplier's only revenue source to be within the disclosed administrative fees and expects the Supplier to disclose to LSU all sources of revenue earned by administering the LSU plan. The Supplier will be responsible for all facets of the day to day operational administration of LSU's pharmacy benefit plan including, but not limited to adjudications and payment of pharmacy claims, network and rebate management, formulary management, call center operations, clinical management programs, auditing of pharmacies, implementation of cost-savings programs, and general and advisory services regarding pharmacy benefit design and implementation.

Also, the Supplier will provide services in processing and reconciliation of the Retiree Drug Subsidy (RDS) claims for retiree drug cost. It is expected that the Supplier will support LSU's variety of program offerings and initiatives. The Supplier will work with LSU, LSU appointed plan Suppliers and actuaries which are responsible for managing the LSU First Health plan. LSU reserves the right to change its health plan at any time during the period of the contract.

SUPPLIER REQUIREMENTS

Satisfaction Guarantee/Account Satisfaction

- Supplier will provide an Implementation Satisfaction guarantee that is separate from all other performance guarantees.
 - The Implementation Satisfaction guarantee will be at the sole discretion of LSU, in that the LSU can determine, in good faith, between responses such as "Yes, LSU is satisfied with the implementation", "No, LSU is not satisfied with the implementation", or "LSU is x% satisfied with the implementation".
 - (Confirm "Yes" or "No"; Amount at risk is requested within the "Financial Offer")
- Supplier will provide an annual Account Management Satisfaction guarantee.
 - The Account Management Satisfaction guarantee will be at the sole discretion of LSU, in that LSU can determine, in good faith, between responses such as "Yes, LSU is satisfied with the performance of the Account

Team and related integral support", "No, LSU is not satisfied with the performance of the Account Team and related internal support", or " LSU is x% satisfied with the performance of the Account Team and related internal support".

- Supplier will provide an annual Consultant and Partner Vendors Satisfaction guarantee.
 - The Account Management Satisfaction guarantee will be at the sole discretion of the Consultant and Partner Vendors, in that the Consultant and Partner Vendors can determine, in good faith, between responses such as "Yes, the Consultant and Partner Vendors is satisfied with the performance of the Account Team and related integral support", "No, the Consultant and Partner Vendors is not satisfied with the performance of the Account Team and related internal support", or "The Consultant and Partner Vendors is x% satisfied with the performance of the Account Team and related internal support".
 - While the Consultant and Partner Vendors will complete the survey, any financial penalties would go to LSU.
- Supplier will guarantee a result of 95% from a member satisfaction survey.
 - Satisfied will be defined as achieving the 80% threshold or better. (i.e., a "4" on a "5" scale).
- Supplier will provide a Termination Satisfaction guarantee that is separate from all other performance guarantees.
 - The Termination Satisfaction guarantee will be at the sole discretion of LSU, in that the university can determine, in good faith, between responses such as "Yes, LSU is satisfied with the termination process", "No, LSU is not satisfied with the termination process", or " LSU is x% satisfied with the termination process".
 - The termination process will include Supplier's performance from the point of notification of termination through post-termination deliverables.
 - (Confirm "Yes" or "No"; Amount at risk is requested within the "Financial Offer")

Communication Requirements

- Supplier agrees to four (4) in person meetings with LSU annually, and up to weekly calls via phone (at LSU's discretion). Additionally, meeting materials delivered electronically to LSU at least three (3) business days in advance of the meeting and will follow-up on all open issues within three (3) business days after the meeting.
- Supplier will guarantee that all inquiries and issues sent to the Account Management team will be responded to within 1 business day.
 - For inquiries and issues that cannot be resolved within 1 business day, the Account Team will add them to an issue tracking log and provide an update on weekly call (or more frequently via email is at LSU request).
 - Updates will be made at least every 7 calendar days.
- Supplier will guarantee that all responses to LSU contract inquiries, redlines, etc. will be provided within 10 business days of receipt, and all open issues will be resolved in good faith within 14 business days.

- Supplier will conduct an annual benefit plan review 45 days prior to effective date of any plan benefit changes, i.e. copayments, co-insurance, clinical rules, etc.
- Supplier will guarantee that all member communications will be sent to impacted members 90 days in advance of the plan change, including formulary changes
- Supplier will guarantee to issue at least 99% of all new member ID cards within 4 business days following receipt of a clean eligibility file
- Supplier will guarantee that 100% of member calls that are transferred to a pharmacist or supervisor will be answered within 5 minutes
- Supplier will guarantee that, on average, 100% of calls will be answered by a live voice within 20 seconds or less.
 - This is measured as the amount of time that elapses between the time a call is received into a member service queue to the time the phone is answered by a Customer Service Representative. Measurement excludes calls routed to IVR
- Supplier will guarantee that 2% or less of calls will be abandoned before the call is answered by Customer Service Representative.
- Supplier will guarantee that at least 98% of all calls will be resolved at the first point of contact.
- Supplier will guarantee to provide digital call recordings within 2 business days of request.
- Supplier will promptly review and respond to requests for prior approval for specific drugs following receipt of all required information.
- Supplier will guarantee a response no later than within 2 business days
- Supplier will guarantee that 100% of all e-mailed member inquiries will be responded to and resolved within 48 hours.

Payment/Claims Processing Requirements

- Supplier will charge all base and ancillary administration fees on a per net paid claim basis.
- Pass-through rates are defined as charging LSU the same amount that is paid to the retail pharmacies and to mail order pharmacies (if not wholly owned).
- Supplier will use Medi-Span as the source of AWP.
 - The AWP price will be based on the actual 11-digit NDC of the package size dispensed on the date dispensed.
 - Supplier will use the NDC of the original packaging manufacturer rather than repackaged NDC.
 - Supplier's definitions of "Brand" and "Generic" will be based on the following:
 - A drug with a Medi-Span code of "Y" on the date dispensed will be considered a generic; all other Medi-Span codes ("M","N","O") will be considered brands.
 - Supplier will not exclude single-source generics, dual-source generics or triple-source generics and will not reclassify generics to brands.
- Supplier will guarantee that 100% of retail direct reimbursement claims will be processed for payment or rejected and responded to within 5 business days
- Supplier will guarantee that the mail order turnaround time for prescription drugs requiring no intervention will be 99% shipped within 2 business days (measured in

business days from the date the prescription drug claim is received by the Supplier either paper, phone, fax or e-prescribed

- Supplier will guarantee that the mail order turnaround time for prescription drugs requiring administrative/clinical intervention will be 100% shipped within 5 business days
- Supplier will calculate, report, and pay all financial settlements (including but not limited to formulary guarantee true-up, discount and dispensing fee guarantees for retail/mail/specialty, clinical program guarantees, minimum rebate guarantees, etc.) to LSU within 90 days from the close of each reporting period.
 - The penalty for this stand-alone guarantee is \$100,000 for EACH reconciliation that is not provided within 90 days from the close of each reporting period.
- Upon termination, your organization agrees to pay LSU all rebates received within 90 days after the end of the agreement.
 - Rebates received after 90-days after termination will be paid to LSU in full.
 - All pricing guarantees will be true up and any shortfalls will be paid to LSU within 90 days after termination.
- Supplier can reject or add a prior authorization to Compound Drugs at point of sale at no additional cost.

Reporting Requirements

- Supplier acknowledges that data captured in the administration of the pharmacy plan belongs to LSU and will deliver ad hoc data request to LSU within 10 business days of request.
- Supplier will guarantee delivery of standard financial and clinical reports within 30 days from the close of each reporting period
- Supplier will guarantee that each quarterly report will be provided to LSU 5 business days prior to the meeting.
- Supplier will provide Quarterly Rebate Reporting within 90 days of the end of the quarter showing Billing/Invoiced/Collected/Paid amounts.

Retail Network Pricing Requirements

- Supplier's contract and adjudication system will reflect the below claim billing formula:
 - Lower of AWP-X%+dispensing fee, MAC + dispensing fee, or U&C.
 - AWP-X% represents your organization's most aggressive retail pharmacy contract rate with each pharmacy.
 - Aggregate annual guaranteed brand discounts are requested on the "Financial Offer" tab.
- Supplier guarantees that both the plan sponsor and member will receive the financial benefit of U&C pricing.
- Supplier guarantees that the member will always pay the "lowest of 3" (discounted price, copay, U&C) and that any excess copay from the member will not be retained by your organization.
- Supplier guarantees that there is no minimum charge at retail for any transaction at any retail network store.

- Supplier guarantees that member contributions (copays, coinsurance, selection penalties, ancillary charges, etc.) will not be included in any calculations:
 - Calculations include adjudication, billing, guarantee reconciliation, etc.
- Supplier guarantees that no other monies (audit/clinical/therapeutic interchange, DUR savings) will be included in any calculations:
 - Calculations include adjudication, billing, guarantee reconciliation, etc.
- Supplier guarantees that the AWP and AWP discount on the date of service will be used for billing and guarantee reconciliation.
- Supplier will confirm if a dispensing fee should be included in the U&C Price.
- Supplier guarantees that there is no minimum charge at mail for any transaction.
- Supplier guarantees that your organization will offer separate rebate guarantees for Mail, Retail, Retail 90, Specialty, and Retail Specialty. (Retail 90 only when such network is specifically requested.)
 - The following will serve as a calculation example:
 - Generic AWP = \$10; Discounted Ingredient Cost = \$6; Member Copay = \$6 (Zero Balance Due from plan).
 - Billed AWP discount and AWP discount for guarantee reconciliation = AWP-40%.
- Supplier guarantees that all brand claims (single source, multi-source, formulary, non-formulary etc.) will be included in the minimum rebate guarantee, regardless of DAW penalty. Minimum rebate guarantee cannot exclude any brand claim that is filled as brand claim, regardless of how the claim is billed.
- Supplier guarantees that brand claims where the member paid 100% of the claim (Zero Balance Due from plan) will be included in the brand claim count of the calculation.
- Supplier ensures that rebate guarantees are for actual rebates received from pharmaceutical manufacturers and do not include other amounts including, but not limited to, therapeutic interchange savings.
- Supplier will use the NDC of the original packaging manufacturer rather than repackaged NDC.
- Supplier's definitions of "Brand" and "Generic" will be based on the following:
 - A drug with a Medi-Span code of "Y" on the date dispensed will be considered a generic; all other Medi-Span codes ("M", "N", "O") will be considered brands.
- Supplier will not exclude single-source generics, dual-source generics or triple-source generics and will not reclassify generics to brands.

Formulary Rebate Requirements

- Supplier will pass through 100% of all rebates including, but not limited to:
 - Base rebates, incentive rebates, manufacturer administrative fees, inflation price protection and all other monies received from pharmaceutical manufacturers.
- Supplier will propose a minimum rebate guarantee per brand claim, measured and reconciled annually to the percent share.

Mail Pricing Requirements

- Supplier guarantees that your organization will propose MAC pricing at mail.

- The Mail MAC list and price schedule will be the same (or better) as the Retail MAC list and pricing schedule.
- Supplier's contract and adjudication system will reflect the below claim billing formula:
 - Lower of AWP-X%+dispensing fee or MAC + dispensing fee.
 - AWP-X% represents a minimum fixed discount for all claims should the MAC price be less aggressive.
 - Aggregate annual guaranteed brand discounts are not requested.
- Supplier guarantees that the member will always pay the lowest of discounted price or copay.
 - Any excess copay from the member will not be retained by your organization.
- Supplier guarantees that the mail service dispensing fee will be \$0.00 and not increased during the contract period for reasons such as: Postage increases, Shipping & Handling increases, etc.
- Supplier will use the NDC of the original packaging manufacturer rather than repackaged NDC.
- Supplier's definitions of "Brand" and "Generic" will be based on the following:
 - A drug with a Medi-Span code of "Y" on the date dispensed will be considered a generic; all other Medi-Span codes ("M", "N", "O") will be considered brands.
- Supplier will not exclude single-source generics, dual-source generics or triple-source generics and will not reclassify generics to brands.

Financial Guarantee Requirements

- All financial guarantees in Supplier's financial proposal will be guaranteed on a contract year basis.
- All guarantees will be trued up individually; no guarantees can be cross-subsidized (surplus offsetting shortfalls, etc.) between delivery channels or within a delivery channel (Retail 30 and Retail 90 are considered separate delivery channels).
- Surplus on any financial guarantee is retained by LSU

Risk Requirements

- Risk on guarantees shall be dollar for dollar on any shortfall with no limit to the amount at risk.

Market Check Requirements

- Supplier will allow fair and flexible market checks throughout the initial agreement to preserve competitiveness of financial terms.
 - Such market checks annually and will be conducted by LSU's third-party consultant of their choosing.
- Supplier guarantees that if market check audit report indicates current market conditions can yield a 1% or more savings of net plan costs, the parties will reach mutual agreement on revised pricing terms and other applicable provisions.
- Supplier guarantees that if mutual agreement cannot be reached within 60 days from the date of the Market check audit report, LSU has the right to terminate the agreement upon 30 days prior written notice.
- Supplier allows LSU to terminate the agreement with or without cause, and without termination charges, with 90 days written notice.

- LSU will be the only party to have termination for convenience rights.

PAYMENTS: In consideration of the services described above, the University agrees to pay Supplier a maximum fee of **\$TOTAL AMOUNT**. Payment will be made on approval of (NAME OF PERSON APPROVING INVOICES). If progress and/or completion to the reasonable satisfaction of the University Department is obtained, payments are scheduled as follows: Upon completion of services and receipt of approved invoice, Supplier shall be paid \$_____. Travel expenses will not be reimbursed to Supplier.

Invoices should be sent to the following address: Attn: (Name of person approving invoices), Louisiana State University, (Department Address), Baton Rouge, LA 70803.

TAXES: Supplier shall be responsible for the remission of all taxes including but not limited to income, employment, use and sales taxes (Federal, State and local) and all license fees, or any other necessary expense to the operation under the Agreement with the University, and shall conform to all laws, regulations, and ordinances applicable to the performance of this contract and any subsequent agreement between the University and Supplier.

ASSIGNMENT: This contract or any portion thereof, or any interest therein, shall not be assigned, transferred, conveyed, sublet, or disposed of without receiving prior written consent of the University. All Agreements and stipulations herein contained, and all obligations assumed in the contract shall be binding upon the heirs, successor and assigns of the parties thereto.

AUDIT/RETENTION OF RECORDS

Audit of Persons Submitting Cost or Pricing Data: The University may, at reasonable times and places, audit the books and records of any person who has submitted cost or pricing data to the extent that such books and records relate to such cost or pricing data.

Right To Audit: The University shall be entitled to audit the books and records of a Supplier or any subcontractor under any negotiated contract or subcontract other than a firm fixed-price contract to the extent that such books and records relate to the performance of such contract or subcontract. Such books and records shall be maintained by the Supplier for a period of five (5) years from the date of final payment under the contract and by the subcontractor for a period of five (5) years from the date of final payment under the subcontract.

Third Party Audit: LSU has the right to hire an independent third-party auditor, if LSU deems necessary, to review all accounts, procedures, matters, and records, and Supplier and/or subcontractor/Supplier shall provide access to all files, information systems access, and space access upon request of LSU for the third-party selected to perform such audit.

In the event that an examination of records results in a determination that previously paid invoices included charges which were improper or beyond the scope of the Contract, Supplier agrees that the amount paid to the Supplier shall be adjusted accordingly, and that the Supplier shall within thirty (30) days thereafter issue a remittance to LSU of any payment declared to be improper or beyond the scope of the contract. In combination therewith, or alternatively, LSU may offset the amounts deemed improper or beyond the scope of the contract against Supplier's outstanding or subsequent invoices, if any.

DIVERSE SUPPLIER(S): Supplier understands that LSU, as the state's flagship university, has an interest in providing entrepreneurial opportunities to diversity-owned businesses. The university is dedicated to promoting the growth and development of minority, women, and small and historically underutilized businesses ("Diverse Businesses") by providing opportunities to participate in university contracts.

In support of this commitment, the Supplier shall use good faith and best efforts to provide opportunities to Diverse Businesses that are either certified by the state or another certifying entity in a diverse category, as a subcontractor or Supplier under this agreement.

If applicable, Supplier shall provide LSU with a list of diversity-owned businesses during each contract year, the list of businesses should identify: (1) the name of the business; (2) its principal office or address; (3) the owner(s); and (4) the services or goods that it may provide or supply and the value of the goods or services procured from the businesses included on Supplier's list.

To the extent that any federal or state law, rule, or regulation would require that this section be modified or voided, the parties agree that such provision can be amended or severed from the agreement without affecting any of the other terms of the agreement.

EEOC/DISCRIMINATION CLAUSE: The Supplier agrees to abide by the requirements of the following as applicable: *Title VI of the Civil Rights Act of 1964 and Title VII of the Civil Rights Act of 1964, as amended by the Equal Employment Opportunity Act of 1972, Federal Executive Order 11246 as amended, the Rehabilitation Act of 1973, as amended, the Vietnam Era Veteran's Readjustment Assistance Act of 1974, Title IX of the Education Amendments of 1972, the Age Discrimination Act of 1975, the Fair Housing Act of 1968 as amended, and Supplier agrees to abide by the requirements of the Americans with Disabilities Act of 1990.* Supplier agrees not to discriminate in its employment practices, and will render services under this contract without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran status, political affiliation, disability, or age in any matter relating to employment. Any act of discrimination committed by Supplier, or failure to comply with these statutory obligations when applicable shall be grounds for termination of this contract.

ADA Compliance: Supplier represents they are committed to promoting and improving accessibility of all their products as required in the Louisiana State University Policy Statement 31 (https://lsu.edu/policies/ps/ps_31.pdf), and will remain committed throughout the term of this agreement. If the products and/or services are not in conformance with all applicable federal and state disability laws, policies, and regulations, Supplier shall use reasonable efforts to update the products and/or services to ensure conformance as soon as possible. In the event any issues arise regarding Supplier's compliance with applicable federal or state disability laws, policies, and regulations, the University will send communications to the Supplier regarding the complaint, and Supplier shall assign a person with accessibility expertise to reply to the University within two business days. Failure to confirm with this requirement shall be justification to cancel agreement/contract for cause.

CONTENT OF CONTRACT/ ORDER OF PRECEDENCE: In the event of an inconsistency between the contract, the RFP and/or the Supplier's Proposal or any other required submissions, the inconsistency shall be resolved by giving precedence first to the final contract, then to the RFP and subsequent addenda (if any) and finally, the Supplier's Proposal or other submissions.

OWNERSHIP: All records, reports, documents and other material delivered or transmitted to Supplier by University shall remain the property of University, and shall be returned by Supplier to University, at

Supplier's expense, at termination or expiration of this contract. All records, reports, documents, or other material related to this contract and/or obtained or prepared by Supplier in connection with the performance of the services contracted for herein shall become the property of University, and shall, upon request, be returned by Supplier to University, at Supplier's expense, at termination or expiration of this contract.

NONASSIGNABILITY: No Supplier shall assign any interest in this contract by assignment, transfer, or novation, without prior written consent of the University. This provision shall not be construed to prohibit the Supplier from assigning his bank, trust company, or other financial institution any money due or to become due from approved contracts without such prior written consent. Notice of any such assignment or transfer shall be furnished promptly to the University.

CONTRACT CHANGES: No additional changes, enhancements, or modifications to any contract resulting from this RFP shall be made without the prior approval of LSU Procurement Services. No oral understanding or agreement not incorporated in the contract is binding on any of the parties.

Changes to the contract include any change in compensation; beginning/ ending date of the contract; scope of work; and/or Supplier change through the Assignment of Contract process. Any such changes, once approved, will result in the issuance of an amendment to the contract.

GOVERNING LAW: All activities associated with this RFP process shall be interpreted under Louisiana Law. All Proposals and contracts submitted are subject to provisions of the laws of the State of Louisiana, the Higher Education Procurement Code (LAC 34:XIII), purchasing rules and regulations; executive orders; standard terms and conditions; special terms and conditions; and specifications listed in this RFP.

TERMINATION FOR CAUSE: The University may terminate this contract for cause based upon the failure of the Supplier to comply with the terms and/or conditions of the Contract, provided that the University shall give the Supplier written notice specifying the Suppliers failure. If within thirty (30) days after receipt of such notice, the Supplier shall not have either corrected such failure or, in the case which cannot be corrected in thirty (30) days, begun in good faith to correct said failure and thereafter proceeded diligently to complete such correction, then the University may, at its option, place the Supplier in default and the contract shall terminate on the date specified in such notice. The Supplier may exercise any rights available to it under Louisiana law to terminate for cause upon the failure of the University to comply with the terms and conditions of this contract; provided that the Supplier shall give the University written notice specifying the University's failure and a reasonable opportunity for the University to cure the defect.

TERMINATION FOR CONVENIENCE: The University may terminate the contract at any time by giving thirty (30) days written notice to the Supplier. The Supplier shall be entitled to payment for deliverables in progress, to the extent work has been performed satisfactorily.

TERMINATION FOR NON-APPROPRIATION OF FUNDS: The continuance of the contract is contingent upon the appropriation of funds to fulfill the requirements of the contract by the legislature. If the legislature fails to appropriate sufficient monies to provide for the continuation of the contract, or if such appropriation is reduced by the veto of the Governor or by any means provided in the appropriations act or Title 39 of the Louisiana Revised Statutes of 1950 to prevent the total appropriation for the year from exceeding revenues for that year, or for any other lawful purpose, and

the effect of such reduction is to provide insufficient monies for the continuation of the contract, the contract shall terminate on the date of the beginning of the first fiscal year for which funds are not appropriated.

INFORMATION SECURITY: Supplier agrees to comply with all applicable laws, regulations, and University policies, including, but not limited to, PS-30 (Student Privacy Rights), PS-113 (Social Security Number Policy), PS-114 (Security of Computing Resources Policy) and the Louisiana Database Breach Notification Law [Act 499]). In addition, Supplier shall implement appropriate measures designed to ensure the confidentiality and security of *protected information*, protect against any anticipated hazards or threats to the integrity or security of such information, and protect against unauthorized access to or use of such information that could result in substantial harm or inconvenience. Supplier also agrees that security breaches, or incidents shall be reported immediately to the University.

“Protected information” shall be defined as data or information that has been designated as private, protected, or confidential by law or by the University. Protected information includes, but is not limited to, employment records, medical records, student records, education records, personal financial records (or other individually identifiable information), research data, trade secrets and classified government information. Protected information shall not include public records that by law must be made available to the general public. To the extent there is any uncertainty as to whether any data constitutes protected information, the data in question shall be treated as protected information until a determination is made by the University.

ALTERATIONS: Any alterations, variations, modifications, or waivers of provisions of this agreement shall be valid only when they have been reduced to writing, duly signed, and attached to the original of this agreement. No claim for services furnished or requested for reimbursement by Supplier, not provided for in this agreement, shall be allowed by University. It is the responsibility of the Supplier to advise the University in advance if contract funds or contract terms may be insufficient to complete contract objectives.

SUPPLIER INDEMNIFICATION: Supplier shall defend, indemnify, and hold harmless the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College and its members, officers, employees and agents (collectively, “LSU Parties”) from and against all suits, actions, claims, judgments, damages, losses or other liabilities, and all cost and expenses, including without limitation reasonable attorney fees, (“Claims”) incurred by LSU Parties in connection therewith, arising out of or relating to Supplier’s: (i) breach of any material term of this Agreement; or (ii) acts or omissions of Supplier, or those of its employees and/or agents. Supplier shall give prompt written notice to LSU of any such Claim. In any instance to which the foregoing indemnities pertain, LSU Parties shall cooperate fully with and assist Supplier in all respects in connection with any such defense, and no LSU Party shall enter into a settlement of such Claim or admit liability or fault on the part of Supplier without Supplier’s prior written approval.

LSU INDEMNIFICATION: LSU Parties shall defend, indemnify and hold harmless Supplier, its directors, officers, employees, agents and assigns, from and against all Claims incurred by Supplier in connection therewith, arising out of or relating to the gross negligence or willful misconduct of any LSU Party. Supplier shall give prompt written notice to LSU of any such Claim. In any instance to which the foregoing indemnities pertain, Supplier shall cooperate fully with and assist LSU in all respects in connection with any such defense, and Supplier shall not enter into a settlement of such Claim or admit liability or fault on the part of LSU without LSU’s prior written approval.

INSURANCE: The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College (henceforth referred to as "University") requires Suppliers/vendors to procure the below minimum limits. The insurance must be maintained for the duration of work performed for or on behalf of the University, and for the length of any agreement with the University. Failure to maintain the required insurance throughout the term of the Agreement shall be a material breach and shall entitle University to all remedies provided for in the Agreement, or by operation of law. The minimum insurance requirements described herein do not in any way limit the Supplier /vendors' financial responsibilities as outlined in the agreement's Indemnification requirements. Therefore, the Supplier/vendor may opt to have broader coverage and limits to satisfy its financial obligations.

Workers' Compensation

Workers' Compensation insurance shall be in compliance with the laws of the state in which the company is domiciled. Employer's Liability shall be included with a minimum limit of \$1,000,000 per accident/per disease/per employee. If Supplier/Contractor is exempt from workers' compensation or fails to provide appropriate coverage, then the Supplier /Contractor is or agrees to be solely responsible and hold harmless the University for the Injuries of any owners, agents, volunteers, or employees during the course of the agreement.

Commercial General Liability (CGL)

Commercial General Liability insurance shall be maintained on an "occurrence" basis, including property damage, bodily injury, products & completed operations, and personal & advertising injury with limits not less than \$1,000,000 per occurrence and \$2,000,000 aggregate on Insurance Services Office Form CG 00 01, ISO 2007 edition or equivalent.

Automobile Liability

Automobile Liability Insurance shall have a minimum combined single limit per accident of \$1,000,000 on ISO form number CA 00 01 or equivalent. This insurance shall include third-party bodily injury and property damage liability for owned, hired and non-owned vehicles.

Excess Insurance

Umbrella or Excess insurance may be used to meet the minimum limit requirements for liability insurance.

Other Insurance Requirements

Additional Insured Status

The University is to be listed as an Additional Insured on the Commercial General Liability (must use an endorsement at least as broad as ISO Form CG 20 10 11 85 or both CG 20 10 and CG 20 37 forms with edition date 2004 if later revisions used). See *Verification of Coverage* section on how the University should be listed as an Additional Insured.

Waiver of Subrogation/Recovery

All insurances shall include a waiver of subrogation/recovery in favor of the University.

Primary Coverage and Limits of Insurance

For any claims related to work performed for or on behalf of the University or related to an agreement/purchase order, the Supplier /Contractor's insurance coverage shall be primary

insurance as respects to the University. Any applicable insurance or self-insurance maintained by the University shall be excess of the Supplier /Contractor's insurance and shall not contribute with it.

Subcontractors

Subcontractors of the Supplier/Contractor shall be subject to all of the requirements stated herein. Supplier/Contractor shall include all subcontractors as insureds under its policies or shall be responsible for verifying insurance coverages and limits and maintaining Certificates of Insurance for each subcontractor. The University reserves the right to receive from the Supplier /Contractor copies of subcontractors' certificates.

Deductibles and Self-Insured Retentions

Any deductibles or self-insured retentions above \$25,000 must be approved by the University or reduced prior to the commencement of work. The University may require the Supplier/Contractor to provide proof of ability to pay losses and related investigations, claim administration, and defense expenses within the retention.

Acceptability of Insurers

Insurance is to be placed with insurers with a current A.M. Best's rating of no less than A- VII, unless otherwise approved by the University.

Verification of Coverage

The University shall be listed as Additional Insured and Certificate Holder as follows:

**The Board of Supervisors of Louisiana State University
and Agricultural & Mechanical College
213 Thomas Boyd Hall
Baton Rouge, LA 70803**

Certificates of Insurance shall be furnished to the University evidencing the insurance required herein including amendatory endorsements. The University's failure to obtain the required documents prior to the work beginning or acceptance of a non-compliant certificate shall not waive the Supplier/Contractor's obligation to have in place the required insurances or to provide the certificate. The University reserves the right to require certified copies of all the insurance policies, including endorsements.

Special Risks or Circumstances

LSU reserves the right to consider alternate coverage or limits and to modify these requirements, based on the nature of the risk, prior experience, insurer, coverage, or other special circumstances.

UNIVERSITY CONTACT: The University shall appoint a Project Manager for this contract who will provide oversight of the activities conducted hereunder. The Project Manager for this contract is identified below. Notwithstanding the Supplier's responsibility for total management during the performance of this Contract, the assigned University Project Manager shall be the principal point of contact on behalf of the University and will be the principal point of contact for Supplier concerning Supplier's performance under this Contract.

Project Manager:

Telephone:

Email:

TERM OF CONTRACT: This contract shall begin on **BEGINNING DATE and** shall terminate on **ENDING DATE.**

JURISDICTION AND VENUE: The terms of this contract shall be interpreted under Louisiana law. Venue for any claims arising out of this contract is proper in the Nineteenth Judicial District Court, Parish of East Baton Rouge, State of Louisiana.

CONTRACT CONTROVERSIES: Any claim or controversy arising out of this contract shall be resolved by the University Pilot Procurement Code, LAC 34:XIII.1503.

ENTIRE CONTRACT AND ORDER OF PRECEDENCE: This Contract, (together with the Attachments and any exhibits specifically incorporated herein by reference) constitutes the entire contract between the parties with respect to the subject matter.

This contract shall, to the extent possible, be construed to give effect to all provisions contained therein: however, where provisions are in conflict, first priority shall be given to the provisions of the language of the Contract, excluding the Exhibits; second priority shall be given to the Exhibits in the order of their reference number.

THUS DONE AND SIGNED AT _____ on this _____ day of _____, 20____, and, IN WITNESS WHEREOF, the parties have executed this Contract.

WITNESSES' SIGNATURES:

SUPPLIER SIGNATURE:

By: _____
Title: _____

THUS, DONE AND SIGNED AT Baton Rouge, Louisiana on this _____ day of _____, 20____, and, IN WITNESS WHEREOF, the parties have executed this Contract.

WITNESSES' SIGNATURES:

**Board of Supervisors of Louisiana State University and
AGRICULTURAL & MECHANICAL College**

By: _____
Title _____

2020 Preferred Drug Formulary

The following is a list of the most commonly prescribed drugs. It represents an abbreviated version of the drug list (formulary) that is at the core of your prescription plan. The list is not all-inclusive and does not guarantee coverage. In addition to using this list, you are encouraged to ask your doctor to prescribe generic drugs whenever appropriate.

PLEASE NOTE: Brand-name drugs may move to nonformulary status if a generic version becomes available during the year. Not all the drugs listed are covered by all prescription plans; check your benefit materials for the specific drugs covered and the copayments for your prescription plan. For specific questions about your coverage, please call the phone number printed on your member ID card.

KEY

[INJ] - Injectable Drug
Brand-name drugs are listed in CAPITAL letters.
Generic drugs are listed in lower case letters.

A

ABILIFY MAINTENA [INJ]
acetaminophen/codeine
ACTEMRA [INJ]
acyclovir
ADEMPAS
ADVAIR HFA
ADYNOVATE [INJ]
AFSTYLA [INJ]
AIMOVIG [INJ]
AJOVY [INJ]
albuterol nebulization solution
alendronate
allopurinol
ALPHAGAN P 0.1%
alprazolam
ALREX
amiodarone
amitriptyline
amlodipine
amlodipine/benazepril
amlodipine/valsartan
amoxicillin
amoxicillin/potassium clavulanate
anastrozole
ANDRODERM
ANORO ELLIPTA
APRISO
ARALAST NP [INJ]
ARIKAYCE
aripiprazole
ARISTADA [INJ]
ARMONAIR RESPICLICK
ARNUITY ELLIPTA
ASMANEX HFA
ASMANEX TWISTHALER
atenolol
atenolol/chlorthalidone
atomoxetine
atorvastatin
AUSTEDO
AVONEX [INJ]
AZASITE
azelastine nasal spray
azithromycin

B

baclofen
BARACLUDE SOLUTION
BD AUTOSHIELD
DUO NEEDLES
BD ULTRAFINE
INSULIN SYRINGES

BD ULTRAFINE PEN NEEDLES
BELBUCA
benazepril
benzonatate
BEPREVE
BETASERON [INJ]
BETHKIS
BEVESPI AEROSPHERE
BIKTARVY
bisoprolol/hctz
blisovi fe
BOSULIF
BREO ELLIPTA
BRILINTA
budesonide nebulization suspension
bupropion
bupropion ext-release
buspirone
butalbital/acetaminophen/caffeine
BYDUREON [INJ]
BYETTA [INJ]
BYSTOLIC

C

CABOMETYX
CARAC
CARAFATE SUSPENSION
carbidopa/levodopa
carvedilol
cefdinir
cefuroxime axetil
celecoxib
cephalexin
CERDELGA
CEREZYME [INJ]
CETROTIDE [INJ]
CHANTIX
chlorhexidine gluconate
chlorthalidone
CIMDUO
CIPRODEX
ciprofloxacin
citalopram
clarithromycin
CLENPIQ
clindamycin hcl
clindamycin phosphate topical
clindamycin phosphate/benzoyl peroxide
clobetasol propionate
clomiphene citrate
clonazepam
clonidine
clopidogrel
clotrimazole/betamethasone dipropionate
COLCRYS
COMBIGAN
COMBIPATCH
COMBIVENT RESPIMAT

COMETRIQ
COPAXONE 40 MG [INJ]
CORLANOR
COSENTYX [INJ]
CREON
CRINONE
cyanocobalamin [INJ]
cyclobenzaprine

D

DALIRESP
DARAPRIM
DAYTRANA
DESCOXY
desloratadine
desvenlafaxine succinate ext-release
dexamethasone
DEXCOM RECEIVER, SENSOR, TRANSMITTER
dexmethylphenidate ext-release
dextroamphetamine/amphetamine
dextroamphetamine/amphetamine ext-release
diazepam
diclofenac sodium delayed-release
dicyclomine
digoxin
diltiazem ext-release
diphenoxylate/atropine
divalproex delayed-release
divalproex ext-release
DIVIGEL
donepezil
doxazosin
doxycycline hyclate
doxycycline monohydrate
DUAVEE
DULERA
duloxetine delayed-release
DUPIXENT [INJ]
DYNAVIL XR
DYMISTA

E

EDARBI
EDARBYCLOR
ELIQUIS
ELOCTATE [INJ]
EMGALITY [INJ]
EMVERM
enalapril
ENBREL [INJ]
enoxaparin [INJ]
ENSTILAR
ENTRESTO
EPCLUSA
EPIDIOLEX
EPIDUO FORTE

epinephrine auto-injector (by Mylan) [INJ]
EPIPEN, EPIPEN JR [INJ]
ergocalciferol
ERIVEDGE
ERLEADA
erythromycin eye ointment
ESBRIET
escitalopram
estradiol
estradiol patches
estradiol/norethindrone acetate
ESTRING
eszopiclone
EUFLEXXA [INJ]
ezetimibe
ezetimibe/simvastatin

F

famotidine
FARXIGA
fenofibrate
fenofibrate micronized
fenofibric acid delayed-release
fentanyl patches
FETZIMA
FINACEA FOAM
finasteride
FLECTOR
FLOVENT DISKUS
FLOVENT HFA
fluconazole
fluocinonide
fluoxetine
folic acid
FORTEO [INJ]
FRAGMIN [INJ]
FREESTYLE KITS/METERS: FREESTYLE FREEDOM, FREESTYLE FREEDOM LITE, FREESTYLE INSULINX, FREESTYLE LITE
FREESTYLE LIBRE READER, SENSOR
FREESTYLE TEST STRIPS: FREESTYLE, FREESTYLE INSULINX, FREESTYLE LITE
furosemide
FYCOMPA

G

gabapentin
GELNIQUE
gemfibrozil
GENOTROPIN [INJ]
GENVOYA

GILENYA
GLOTRIF
GLASSIA [INJ]
glimpiride
glipizide
glipizide ext-release
GLUCAGEN [INJ]
GLUCAGON [INJ]
glyburide
GLYXAMBI
GONAL-F, GONAL-F RFF, GONAL-F RFF
REDI-JECT [INJ]
GRASTEK
guanfacine ext-release

H

HARVONI
HUMALOG [INJ]
HUMIRA [INJ]
HUMULIN [INJ]
hydralazine
hydrochlorothiazide
hydrocodone/acetaminophen
hydrocodone/chlorpheniramine polistirex ext-release
hydrocortisone topical
hydromorphone
hydroxychloroquine
hydroxyzine hcl
hydroxyzine pamoate
HYSINGLA ER

I

ibandronate
IBRANCE
ibuprofen
ILEVRO
INBRIJA
INCRUSE ELLIPTA
indomethacin
INLYTA
INVELTYS
INVOKAMET
INVOKAMET XR
INVOKANA
irbesartan
IRESSA
isosorbide mononitrate ext-release

J

JANUMET, JANUMET XR
JANUVIA
JARDIANCE
JENTADUETO
JENTADUETO XR
JIVI [INJ]
JULUCA
junel

(continued)

Costs for covered alternatives may vary.

THIS DOCUMENT LIST IS EFFECTIVE JANUARY 1, 2020 THROUGH DECEMBER 31, 2020. THIS LIST IS SUBJECT TO CHANGE.

junel fe

K

ketoconazole topical
ketorolac
KITABIS PAK
KOGENATE FS [INJ]
KOVALTRY [INJ]
KYLEENA

L

labetalol
lamotrigine
LANTUS [INJ]
latanoprost eye solution
LATUDA
LEVEMIR [INJ]
levetiracetam
levocetirizine
levofloxacin
levothyroxine sodium
lidocaine patches
LINZESS
liothyronine
LIPOFEN
lisinopril
lisinopril/hctz
LIVALO
LO LOESTRIN FE
LOKELMA
lorazepam
LORBRENA
losartan
losartan/hctz
LOTEMAX
LOTEMAX SM
lovastatin
LUMIGAN
LUPANETA [INJ]
LUPRON DEPOT
3.75 MG, 11.25 MG [INJ]
LUPRON DEPOT-PED [INJ]

M

MAYZENT
meclizine
medroxyprogesterone
meloxicam
metaxalone
metformin
metformin ext-release
methimazole
methocarbamol
methotrexate
methylphenidate
methylphenidate ext-release
methylprednisolone
metoclopramide
metoprolol succinate
ext-release
metoprolol tartrate
metronidazole
metronidazole topical
metronidazole vaginal
microgestin fe
minocycline
MIRENA
mirtazapine
MIRVASO
MITIGARE
moderiba
MONOVISC [INJ]
montelukast

morphine sulfate ext-release
MOVANTI
moxifloxacin eye solution
mupirocin
MUSE
MYDAYIS
MYRBETRIQ

N

nabumetone
NAMZARIC
naproxen, naproxen sodium
NARCAN NASAL SPRAY
NASCOBAL
neomycin/polymyxin/
hydrocortisone ear solution
niacin ext-release
nifedipine ext-release
nitrofurantoin macrocrystal
NITYR
NIVESTYM [INJ]
NORDITROPIN [INJ]
nortriptyline
NOVAREL [INJ]
NOVOEIGHT [INJ]
NOVOFINE AUTOSHIELD
NEEDLES
NOVOFINE NEEDLES
NOVOTWIST NEEDLES
NUCALA [INJ]
NUCYNTA, NUCYNTA ER
NUDEXTA
nystatin
nystatin topical

O

ODACTRA
OFEV
ofloxacin
olanzapine
olmesartan
olmesartan/hctz
olopatadine eye solution
omega-3 acid ethyl esters
ondansetron
ondansetron orally
disintegrating tablets
ONETOUCH KITS/METERS:
ULTRA 2, ULTRAMINI,
VERIO, VERIO FLEX
ONETOUCH TEST STRIPS:
ULTRA, VERIO
ONEXTON
OPSUMIT
ORACEA
ORALAIR
ORILISSA
ORTHOVISC [INJ]
oseltamivir
OTEZLA
OTOVEL
OTREXUP [INJ]
OVIDREL [INJ]
oxcarbazepine
oxybutynin ext-release
oxycodone
oxycodone/acetaminophen
OXYCONTIN
OZEMPIC [INJ]

P

pantoprazole delayed-release
paroxetine hcl

PAZEO
penicillin v potassium
PENTASA
PERFOROMIST
PHOSLYRA
PICATO
pioglitazone
PLEGRIDY [INJ]
polymyxin/trimethoprim
eye solution
POMALYST
potassium chloride
ext-release
PRALUENT [INJ]
pramipexole
pravastatin
PRECISION XTRA METERS,
TEST STRIPS,
B-KETONE STRIPS
prednisolone acetate
eye suspension
prednisolone sodium
phosphate
prednisone
pregabalin
PREMARIN CREAM
PREMARIN TABLETS
PREMPHASE
PREMPRO
PREPOPIK
PROAIR HFA
PROAIR RESPICLICK
PROCRIT [INJ]
progesterone micronized
PROLASTIN C [INJ]
PROLENSA
promethazine
promethazine/
dextromethorphan
propranolol
propranolol ext-release
PULMICORT FLEXHALER
PYLERA

Q

QBREXZA
QNASL
QUDEXY XR
quetiapine
QUILLICHEW ER
QUILLIVANT XR
quinapril
QVAR
QVAR REDIHALER

R

rabeprazole
RAGWITEK
raloxifene
ramipril
ranitidine
RASUVO [INJ]
REBIF [INJ]
RECTIV
RELISTOR [INJ]
RELISTOR TABLETS
REMICADE [INJ]
RESTASIS
RETACRIT [INJ]
REVLIMID
RHOPRESSA
risperidone
rizatriptan

ropinirole
rosuvastatin
RUBRACA
RUCONEST [INJ]

S

SAVELLA
SEGLUROMET
SEREVENT DISKUS
sertraline
sildenafil
SIMPONI 100 MG (for
ulcerative colitis only) [INJ]
simvastatin
SKYLA
SKYRIZI [INJ]
SOLIQUA [INJ]
SOMATULINE DEPOT [INJ]
SOOLANTRA
spironolactone
sprintec
SPRYCEL
STEGLATRO
STELARA SC [INJ]
sulfamethoxazole/
trimethoprim
sumatriptan
SUNOSI
SUPREP
SUTENT
SYMBICORT
SYMFI
SYMFI LO
SYMJEPI [INJ]
SYMLINPEN [INJ]
SYMPROIC
SYNJARDY, SYNJARDY XR

T

TACLONEX SUSPENSION
tacrolimus topical
tadalafil
TALZENNA
tamoxifen
tamsulosin ext-release
TASIGNA
TAYTULLA
TAZORAC GEL
TAZORAC 0.05% CREAM
TECFIDERA
TEKTURNA HCT
terazosin
terconazole vaginal
testosterone cypionate [INJ]
THALOMID
timolol maleate eye solution
tizanidine
TOBI PODHALER
TOBRADEX OINTMENT
TOBRADEX ST
tobramycin eye solution
tobramycin/dexamethasone
eye suspension
topiramate
TOUJEO [INJ]
TOVIAZ
TRADJENTA
tramadol
TRAVATAN Z
trazodone
TRELEGY ELLIPTA
TREMIFYA [INJ]
TRESIBA [INJ]
triamcinolone topical
triamterene/hctz

tri-lo-marzia
trinessa
TRIPTODUR [INJ]
tri-sprintec
TRIUMEQ
TRULANCE
TRULICITY [INJ]
TYMLOS [INJ]

U

UCERIS FOAM
UDENYCA [INJ]
UPTRAVI

V

valacyclovir
valsartan
valsartan/hctz
VARUBI
VASCEPA
VELPHORO
venlafaxine
venlafaxine ext-release
VENTOLIN HFA
verapamil ext-release
VERZENIO
VIBERZI
VIIBRYD
VIMPAT
VIOKACE
VIZIMPRO
VYVANSE

W

warfarin

X

XALKORI
XARELTO
XELJANZ, XELJANZ XR
XIFAXAN
XIGDUO XR
XIIDRA
XOLAIR [INJ]
XTANDI
XULTOPHY [INJ]
XYREM

Y

YONSA
YUPELRI
yuvaferm

Z

ZARXIO [INJ]
ZENPEP
zolpidem
zolpidem ext-release
ZOMIG NASAL
ZTLIDO
ZUBSOLV
ZYLET
ZYTIGA 500 MG

Costs for covered alternatives may vary.

THIS DOCUMENT LIST IS EFFECTIVE JANUARY 1, 2020 THROUGH DECEMBER 31, 2020. THIS LIST IS SUBJECT TO CHANGE.

2020 Preferred Drug Formulary

The excluded medications shown below are not covered on the preferred drug list. In most cases, if you fill a prescription for one of these drugs, you will pay the full retail price.

Take action to avoid paying full price. If you're currently using one of the excluded medications, please ask your doctor to consider writing you a new prescription for one of the following preferred alternatives. Additional covered alternatives may be available. Costs for covered alternatives may vary. Not all the drugs listed are covered by all prescription plans; check your benefit materials for the specific drugs covered and the copayments for your plan. For specific questions about your coverage, please call the number on your member ID card.

Drug Class	Excluded Medications	Preferred Alternatives
ANTIINFECTIVES Antibiotics	DOXYCYCLINE HYCLATE DR 80 MG	doxycycline hyclate dr
Antifungal Agents (Oral)	TOLSURA	itraconazole
Antivirals (Oral)	SITAVIG	acyclovir oral or cream, famciclovir, valacyclovir
AUTONOMIC & CENTRAL NERVOUS SYSTEM Alpha-2 Adrenergic Agonists (for Opioid Withdrawal)	LUCEMYRA	clonidine
Anticonvulsants	TOPIRAMATE ER CAPSULES	topiramate tablets, QUDEXY XR
Anti-Migraine Therapy	ONZETRA XSAIL	sumatriptan nasal spray, ZOMIG NASAL SPRAY
	SUMAVEL DOSEPRO	sumatriptan injection
Antiparkinsonism Agents	GOCOVRI ER, OSMOLEX ER	amantadine capsules, amantadine tablets, amantadine oral solution
	XADAGO	rasagiline, selegiline
Antipsychotics (Oral)	ABILIFY MYCITE	aripiprazole tablets
Duchenne Muscular Dystrophy (DMD) Agents	EMFLAZA	prednisone solution, prednisone tablets
	EXONDYS 51	No alternatives recommended
Long-Acting Opioid Oral Analgesics	EMBEDA, OXYCODONE ER	hydromorphone ER, morphine sulfate ER, oxymorphone ER, HYSINGLA ER, NUCYNTA ER, OXYCONTIN
Multiple Sclerosis (Beta Interferons)	EXTAVIA	AVONEX ADMINISTRATION PACK, AVONEX PEN, BETASERON, PLEGRIDY, REBIF, REBIF REBIDOSE
Multiple Sclerosis (Oral)	AUBAGIO	GILENYA, MAYZENT, TECFIDERA
Narcotic Analgesics & Combinations	APADAZ, BENZHYDROCODONE/ACETAMINOPHEN	hydrocodone/acetaminophen
	BUTRANS	buprenorphine patches, BELBUCA
Narcotic Antagonists	EVZIO	naloxone syringes, NARCAN NASAL SPRAY
Neuropathic Agents	LYRICA CR	gabapentin, pregabalin
Tardive Dyskinesia Therapy	INGREZZA	AUSTEDO
Transmucosal Fentanyl Analgesics	ABSTRAL, FENTANYL CITRATE BUCCAL TABLETS, FENTORA, LAZANDA, SUBSYS	fentanyl citrate lozenges
Miscellaneous Antidepressants	SPRAVATO	olanzapine/fluoxetine, bupropion, desvenlafaxine er, duloxetine, escitalopram, mirtazapine, sertraline
CARDIOVASCULAR ACE Inhibitors	EPANED	enalapril
	QBRELIS	lisinopril
Anticoagulants	PRADAXA, SAVAYSA	ELIQUIS, XARELTO
Beta Blockers & Combinations	KAPSPARGO SPRINKLE	metoprolol succinate
	DUTOPROL, METOPROLOL SUCCINATE/HCTZ ER	metoprolol tartrate/hydrochlorothiazide, metoprolol succinate ER plus hydrochlorothiazide
HMG & Cholesterol Inhibitor Combinations	ALTOPREV, EZALLOR SPRINKLE	atorvastatin, fluvastatin er, lovastatin, pravastatin, rosuvastatin, simvastatin, LIVALO

Drug Class	Excluded Medications	Preferred Alternatives
CARDIOVASCULAR (continued) PCSK9 Inhibitors	REPATHA	PRALUENT
DERMATOLOGICAL Oral Agents for Acne	MINOLIRA	minocycline ER
Rosacea Agents (Oral)	DOXYCYCLINE 40 MG CAPSULES	ORACEA
Rosacea Agents (Topical)	RHOFADE	MIRVASO
Topical Acne/Antibiotic Combinations	AKTIPAK, VELTIN	clindamycin/benzoyl peroxide, clindamycin/tretinoin, erythromycin/benzoyl peroxide, ONEXTON
Topical Agents for Actinic Keratosis	FLUOROURACIL 0.5% CREAM, IMIQUIMOD 3.75% CREAM PUMP, ZYCLARA	diclofenac 3% gel, fluorouracil 2% solution, fluorouracil 5% cream, imiquimod 5% cream, CARAC, PICATO
Topical Antifungals	LULICONAZOLE	ciclopirox, econazole, ketoconazole, naftifine, oxiconazole
Topical Corticosteroids	CLOCORTOLONE	betamethasone valerate, fluocinolone acetonide, triamcinolone acetonide
	TOPICORT SPRAY, VERDESO FOAM	desonide 0.05% cream/lotion/ointment, desoximetasone 0.25% cream/ointment
Miscellaneous Topical Dermatological Agents	ALCORTIN A	hydrocortisone, mupirocin
	LIDOCAINE/TETRACAINE	lidocaine cream, lidocaine/prilocaine cream
DIABETES Blood Glucose Meters & Test Strips	BAYER (BREEZE, CONTOUR) NATIONAL MEDICAL (ADVOCATE) OMNIS HEALTH (EMBRACE, VICTORY) ROCHE (ACCU-CHEK) TRIVIDIA (TRUETEST, TRUETRACK) UNISTRIP ALL OTHER METERS & TEST STRIPS THAT ARE NOT LISTED AS PREFERRED	FREESTYLE KITS/METERS: FREESTYLE FREEDOM, FREESTYLE FREEDOM LITE, FREESTYLE INSULINX, FREESTYLE LITE FREESTYLE TEST STRIPS: FREESTYLE, FREESTYLE INSULINX, FREESTYLE LITE ONETOUCH KITS/METERS: ULTRA2, ULTRAMINI, VERIO, VERIO FLEX ONETOUCH TEST STRIPS: ULTRA, VERIO PRECISION XTRA METERS, TEST STRIPS, B-KETONE STRIPS
Dipeptidyl Peptidase-4 Inhibitors & Combinations	ALOGLIPTIN, NESINA, ONGLYZA	JANUVIA, TRADJENTA
	ALOGLIPTIN/METFORMIN, KAZANO, KOMBIGLYZE XR	JANUMET, JANUMET XR, JENTADUETO, JENTADUETO XR
	ALOGLIPTIN/PIOGLITAZONE	pioglitazone plus JANUVIA or TRADJENTA
Glucagon-Like Peptide-1 Agonists	ADLYXIN, VICTOZA	BYDUREON, BYETTA, OZEMPIC, TRULICITY
Insulins	NOVOLIN, RELION NOVOLIN	HUMULIN
	ADMELOG, APIDRA, FIASP, INSULIN LISPRO, NOVOLOG	HUMALOG
EAR/NOSE Nasal Steroids	BECONASE AQ, flunisolide, fluticasone, OMNARIS, ZETONNA	QNASL
Otic Fluoroquinolone Antibiotics	CETRAXAL	ciprofloxacin ear solution, ofloxacin ear solution, CIPRODEX, OTOVEL
ENDOCRINE (OTHER) Combination Patches	CLIMARA PRO	COMBIPATCH
Estrogen and Estrogen Modifiers for Vaginal Symptoms	FEMRING	estradiol patches, estradiol tablets, yuvafem, ESTRING, PREMARIN CREAM, PREMARIN TABLETS
Growth Hormones	HUMATROPE, NUTROPIN AQ NUSPIN, OMNITROPE, SAIZEN, SAIZENPREP, ZOMACTON	GENOTROPIN, NORDITROPIN FLEXPRO
Somatostatin Analogs	SANDOSTATIN LAR DEPOT, SIGNIFOR LAR	SOMATULINE DEPOT
Topical Estrogen Gels	ESTROGEL	DIVIGEL
GASTROINTESTINAL Antiemetics (Oral)	AKYNZEO CAPSULES	granisetron, ondansetron, aprepitant, VARUBI TABLETS
	EMEND POWDER PACKETS	aprepitant, VARUBI TABLETS
Corticosteroids (Rectal Formulations)	CORTIFOAM	hydrocortisone enema, UCERIS FOAM

Drug Class	Excluded Medications	Preferred Alternatives
GASTROINTESTINAL (continued) Inflammatory Bowel Agents	DIPENTUM	balsalazide disodium, mesalamine delayed release, sulfasalazine, APRISO, PENTASA
Pancreatic Enzymes	PANCREAZE, PERTZYE	CREON, ZENPEP
Proton Pump Inhibitors	ACIPHEX SPRINKLE, esomeprazole, lansoprazole, omeprazole, NEXIUM PACKETS, PRILOSEC SUSPENSION, PROTONIX SUSPENSION, RAPERAZOLE DR SPRINKLE, ZEGERID	pantoprazole, rabeprazole
HEMATOLOGICAL Antiplatelet Agents	ASPIRIN/OMEPRAZOLE DR, YOSPRALA DR	aspirin plus OTC omeprazole, pantoprazole or rabeprazole
Chelating Agents	JADENU, JADENU SPRINKLE	deferasirox
Erythropoiesis-Stimulating Agents	ARANESP, EPOGEN, MIRCERA	PROCRIT, RETACRIT
Factor VIII Recombinant Products	NUWIQ, RECOMBINATE, XYNTHA, XYNTHA SOLOFUSE	ADVATE, ADYNOVATE, AFSTYLA, ELOCTATE, JIVI, KOGENATE FS, KOVALTRY, NOVOEIGHT
Granulocyte Colony Stimulating Factors	GRANIX, NEUPOGEN	NIVESTYM, ZARXIO
Thrombocytopenia Agents	MULPLETA	DOPTELET
HEPATITIS Hepatitis C	LEDIPASVIR/SOFOSBUVIR, SOFOSBUVIR/VELPATASVIR, VOSEVI, ZEPATIER	EPCLUSA, HARVONI, MAYVRET, SOVALDI
HIV Antiretrovirals Note: Current patients established on therapy are allowed to continue therapy.	ATRIPLA, DELSTRIGO, SYMTUZA	BIKTARVY, GENVOYA, ODEFSEY, SYMFI, SYMFI LO, TRIUMEQ
	COMPLERA	ODEFSEY
	PIFELTRO	efavirenz, EDURANT
	PREZCOBIX	atazanavir, ritonavir, KALETRA TABLETS, PREZISTA
	STRIBILD	BIKTARVY, GENVOYA
MUSCULOSKELETAL & RHEUMATOLOGY Gout Therapy	COLCHICINE	COLCRYS, MITIGARE
	DUZALLO, ZURAMPIC	allopurinol, probenecid
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)	FENOPROFEN CAPSULES, FENORTHO, NALFON CAPSULES	fenoprofen calcium tablets, diclofenac, ibuprofen, indomethacin, meloxicam, nabumetone, naproxen
	TIVORBEX, VIVLODEX, ZORVOLEX	diclofenac sodium, etodolac, ibuprofen, indomethacin, meloxicam, nabumetone, naproxen, piroxicam
	ZIPSOR	diclofenac potassium, diclofenac sodium
Topical Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)	DICLOFENAC EPOLAMINE PATCHES	FLECTOR PATCHES
	PENNSAID	diclofenac sodium topical, FLECTOR PATCHES
OBSTETRICAL & GYNECOLOGICAL Human Chorionic Gonadotropin	CHORIONIC GONADOTROPIN, PREGNYL	NOVAREL, OVIDREL
Ovulatory Stimulants (Follicle Stimulating Hormone)	BRAVELLE, FOLLISTIM AQ	GONAL-F, GONAL-F RFF, GONAL-F RFF REDI-JECT
Vaginal Progestones	ENDOMETRIN	CRINONE 8% GEL
ONCOLOGY Breast Cancer Agents	KISQALI, KISQALI FEMARA CO-PACK, PIQRAY	IBRANCE, VERZENIO
Multiple Myeloma Agents	XPOVIO	DARZALEX, KYPROLIS, NINLARO, POMALYST, REVLIMID, THALOMID, VELCADE
OPHTHALMIC Antiglaucoma Drugs (Beta-Adrenergic Blockers)	TIMOPTIC OCUDOSE	betaxolol drops, levobunolol drops, timolol drops, ALPHAGAN P 0.1%, COMBIGAN
Antiglaucoma Drugs (Ophthalmic Prostaglandins)	XELPROS, ZIOPTAN	bimatoprost drops, latanoprost drops, LUMIGAN, TRAVATAN Z
Ophthalmic Anti-Allergic	ALOCRIAL, ALOMIDE	azelastine drops, cromolyn drops, olopatadine drops, ALREX, BEPREVE, PAZEO
Ophthalmic Anti-Inflammatory	FML FORTE, FML S.O.P., MAXIDEX, PRED MILD	dexamethasone drops, fluorometholone drops, prednisolone drops, INVELTYS, LOTEMAX

Drug Class	Excluded Medications	Preferred Alternatives
OPHTHALMIC (continued) Ophthalmic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	ACUVAIL, NEVANAC	bromfenac drops, diclofenac drops, ketorolac drops, ILEVRO, PROLENSA
OSTEOARTHRITIS Hyaluronic Acid Derivatives	DUROLANE, GEL-ONE, GELSYN-3, GENVISC 850, HYALGAN, HYMOVIS, SUPARTZ FX, SYNVISC, SYNVISC-ONE, TRIVISC, VISCO-3	EUFLEXXA, MONOVISC, ORTHOVISC
OSTEOPOROSIS Bone Modifiers	EVENITY, PROLIA	alendronate, ibandronate, risedronate, zoledronic acid, FORTEO, TYMLOS
RENAL DISEASE Phosphate Binders	FOSRENOL POWDER PACKETS	lanthanum, sevelamer carbonate, sevelamer hcl, PHOSLYRA, VELPHORO
RESPIRATORY Epinephrine Auto-Injector Systems	AUVI-Q, EPINEPHRINE AUTO-INJECTOR (BY IMPAX)	epinephrine auto-injector (by Mylan), EPIPEN, EPIPEN JR
Immunological Agents for Asthma	CINQAIR	FASENRA, NUCALA
Long-Acting Beta Agonist Inhalers	STRIVERDI RESPIMAT	SEREVENT DISKUS
Long-Acting Muscarinic Antagonist Inhalers	SPIRIVA HANDIHALER, SPIRIVA RESPIMAT, TUDORZA PRESSAIR	INCRUSE ELLIPTA
Long-Acting Muscarinic Antagonist/ Long-Acting Beta-Agonist Combination Inhalers	STIOLTO RESPIMAT	ANORO ELLIPTA, BEVESPI AEROSPHERE
Pulmonary Anti-Inflammatory Inhalers	ALVESCO	ARNUITY ELLIPTA, ASMANEX HFA/TWISTHALER, FLOVENT DISKUS/HFA, PULMICORT FLEXHALER, QVAR REDIHALER
Short-Acting Beta ₂ -Agonist Inhalers	ALBUTEROL SULFATE HFA, LEVALBUTEROL HFA, PROVENTIL HFA, XOPENEX HFA	PROAIR HFA/RESPICLICK, VENTOLIN HFA
WEIGHT LOSS Weight Loss Agents	QSYMIA	benzphetamine, diethylpropion, phentermine
MISCELLANEOUS AGENTS	SIKLOS	DROXIA
	NOCTIVA	desmopressin tablets
Hereditary Angioedema	BERINERT	RUCONEST
Immunosuppressant Agents	XATMEP	methotrexate
Metabolic Agents	ORFADIN	NITYR
Polynuropathy of Hereditary Transthyretin-Mediated Amyloidosis	ONPATTRO	No alternatives recommended
Potassium Binders	VELTASSA	LOKELMA

Excluded Medications, Products at a Glance

ABILIFY MYCITE	CELACYN	FLUOROURACIL 0.5% CREAM	METHITEST
ABILIFY^	CELEBREX^	FML FORTE, FML S.O.P.	METOPROLOL SUCCINATE, HCTZ ER
ABSORICA	CELEXA^	FOCALIN^, FOCALIN XR^	MICARDIS^, MICARDIS HCT^
ABSTRAL	CEQUA	FOLLISTIM AQ	MICROCYN
ACIPHEX SPRINKLE	CERACADE	FORFIVO XL	MILLIPRED PAK
ACIPHEX^	CERAMAX	FORTAMET^	MINASTRIN 24 FE^
ACTICLATE^	CETRAXAL	FOSRENOL CHEWABLE TABLETS^	MINOLIRA
ACUVAIL	CHORIONIC GONADOTROPIN	FOSRENOL POWDER PACKETS	MIRCERA
ACZONE^	CIALIS^	GANIRELIX ACETATE^	MULPLETA
ADCIRCA^	CINQAIR	GEL-ONE	NALFON CAPSULES
ADDERALL^	CLIMARA PRO	GELSYN-3	NAMENDA XR^
ADDYI	CLOCORTOLONE	GENADUR	NASONEX^
ADLYXIN	COLCHICINE	GENVISC 850	NATIONAL MEDICAL (ADVOCATE)
ADMELOG	COMPLERA	GLEEVEC^	NEOSALUS, NEOSALUS CP
ADZENYS XR	CONZIP	GLOPERBA	NESINA
AKTIPAK	COREG^	GLUCOPHAGE^, GLUCOPHAGE XR^	NEUPOGEN
AKYNZEO CAPSULES	CORTIFOAM	GLUMETZA^	NEURONTIN^
ALBUTEROL SULFATE HFA	COSOPT^	GOCOVRI ER	NEVANAC
ALCORTIN A	COZAAR^, HYZAAR^	GRALISE	NIVATOPIC PLUS
ALEVEER DIS	CRESTOR^	GRANIX	NOCTIVA
ALEVICYN	CUPRIMINE^	HORIZANT	NORCO^
ALLZITAL	CYCLOSET	HPR PLUS	NORVASC^
ALOCRIIL	CYMBALTA^	HUMATROPE	NOVACORT
ALOGLIPTIN	CYTOMEL^	HYALGAN	NOVOLIN
ALOGLIPTIN, METFORMIN	DELSTRIGO	HYLATOPIC, HYLATOPIC PLUS	NOVOLOG
ALOGLIPTIN, PIOGLITAZONE	DELZICOL^	HYMOVIS	NUTROPIN AQ NUSPIN
ALOMIDE	DEPRIZINE	IMIQUIMOD 3.75% CREAM PUMP	NUVIGIL^
ALTOPREV	DETROL^, DETROL LA^	IMITREX^	NUWIQ
ALVESCO	DEXERYL	IMPOYZ	OMNARIS
AMBIEN^, AMBIEN CR^	DENPAK	INDERAL LA^	OMNIS HEALTH (EMBRACE, VICTORY)
AMPYRA^	DIAB CREAM, GEL	INGREZZA	OMNITROPE
AMRIX^	DICLOFENAC EPOLAMINE PATCHES	INSULIN LISPRO	ONGLYZA
ANDROGEL 1% [^]	DICOPANOL SUS	INTERMEZZO^	ONPATTRO
ANDROID^	DIOVAN^, DIOVAN HCT^	INTUNIV^	ONZETRA XSAIL
ANUSOL-HC^	DIPENTUM	INVEGA TRINZA	ORFADIN
APADAZ	DOXYCYCLINE 40 MG CAPSULES	ISTALOL^	ORTHO TRI-CYCLEN^, ORTHO TRI-CYCLEN LO^
APIDRA	DOXYCYCLINE HYCLATE DR 80 MG	JADENU, JADENU SPRINKLE	OSMOLEX ER
APLENZIN	DUEXIS	JUBLIA	OXTELLAR XR
ARANESP	DURLAZA	KAMDOY	OXYCODONE ER
ARESTIN	DUROLANE	KAPSPARGO SPRINKLE	PANCREAZE
ARIMIDEX^	DUTOPROL	KAZANO	PATADAY^
ASACOL HD^	DUZALLO	KENDALL HYDROGEL	PENNSAID
ASPIRIN, OMEPRAZOLE DR	EDECIN^	KEPPRA^, KEPPRA XR^	PERTZYE
ASTAGRAF XL	EDLUAR	KERYDIN	PEXEVA
ATACAND^, ATACAND HCT^	EFFEXOR XR^	KISQALI, KISQALI FEMARA CO-PACK	PHLAG SPRAY
ATOPICLAIR	ELETONE	KOMBIGLYZE XR	PIFELTRO
ATRAPRO	ELIDEL^	LAMICTAL^, LAMICTAL ODT^, LAMICTAL XR^	PIQRAY
ATRIPLA	EMBEDA	LATUDA	PLAQUENIL^
AUBAGIO	EMEND CAPSULES^, TRIFOLD PACK^	LAZANDA	PLAVIX^
AUVI-Q	EMEND POWDER PACKETS	LEDIPASVIR, SOFOSBUVIR	PLEXION CLOTH PAD
AVALIDE^, AVAPRO^	EMFLAZA	LEVABUTEROL HFA	PR CREAM
AVAR, AVAR LS	EMULSION SB	LEXAPRO^	PRADAXA
AVO CREAM	ENDOMETRIN	LIBRAX^	PRAVACHOL^
AVODART^	ENTTY	LIDOCAINE, TETRACAINE	PRED MILD
AZOR^	ENVARUSUS XR	LIDODERM^	PREGNYL
BARACLUDE TABLETS^	EPANED	LIPITOR^	PRESERA
BAYER (BREEZE, CONTOUR)	EPICERAM	LOESTRIN^, LOESTRIN FE^	PREVACID^, PREVACID SOLUTAB^
BEAU RX	EPINEPHRINE AUTO-INJECTOR (BY IMPAX)	LOTREL^	PREZCOBIX
BECONASE AQ	EPOGEN	LOVENOX^	PRIOSEC SUSPENSION
BENICAR^, BENICAR HCT^	ESTROGEL	LUCEMYRA	PRISTIQ^
BENZEPRO	EVENITY	LULICONAZOLE	PROLIA
BENZHYDROCODONE, ACETAMINOPHEN	EVZIO	LUNESTA^	PROTONIX SUSPENSION
BERINERT	EXFORGE^, EXFORGE HCT^	LUXAMEND	PROTONIX^
BIAFINE	EXJADE^	LUZU	PROVENTIL HFA
BINOSTO	EXONDYS 51	LYRICA CR	PROVIGIL^
BP FOAM	EXTAVIA	LYRICA^	PROZAC^
BRAVELLE	EZALLOR SPRINKLE	MAVYRET	PRUCLAIR
BRISDELLE^	FEMRING	MAXALT^, MAXALT MLT^	PRUDOXIN
BUPAP^	FENOPROFEN CAPSULES	MAXIDEX	PRUMYX
BUTRANS	FENORTHO	MB HYDROGEL	PRUTECT
CAMBIA	FENTANYL CITRATE BUCCAL TABLETS	MEDI-PATCH PAD	PULMICORT RESPULES^
CAROSPIR	FENTORA	METFORMIN ER (FORTAMET AND	QBRELIS
CARRASYN HYDROGEL	FIASP	GLUMETZA)	QSYMIA

[^] Multisource brand exclusion – The generic equivalent of this brand-name medication is covered under your plan. FDA-approved generic medications meet strict standards and contain the same active ingredients as their corresponding brand-name medications, although they may have a different appearance. As new generic medications become available, additional multisource brand products may become excluded.

Excluded Medications, Products at a Glance

RABEPRAZOLE DR SPRINKLE	STIOLTO RESPIMAT	TUSSICAPS	XRYLIX SHEETS
RADIAGEL	STRATTERA [^]	TUZISTRA XR	XYNTHA, XYNTHA SOLOFUSE
RADIAPLEXRX	STRENSIQ	UNISTRIP	YASMIN [^]
RAPAFLO [^]	STRIBILD	UROXATRAL [^]	YOSPRALA
RAYOS	STRIVERDI RESPIMAT	VAGIFEM [^]	YOSPRALA DR
RECOMBINATE	SUBSYS	VALIUM [^]	ZANABIN
RELADOR PAK	SUMAVEL DOSEPRO	VALTRES [^]	ZAVESCA [^]
RELION NOVOLIN	SUMAXIN [^]	VANATOL LQ	ZEGERID [^]
RENAGEL [^]	SUPARTZ FX	VASCUDERM, VASCUDERM HYDROGEL	ZEMBRACE
RENOVO PAD	SYMTUZA	VELTASSA	ZEPATIER
REPATHA	SYNERDERM	VELTIN	ZERUVIA PAD
RHOFADE	SYNVEXIA TC CREAM 4-1%	VERDESO FOAM	ZETIA [^]
RIOMET	SYNVISC, SYNVISC-ONE	VIAGRA [^]	ZETONNA
ROCHE (ACCU-CHEK)	TESTIM [^]	VICTOZA	ZIANA GEL [^]
SAIZEN, SAIZENPREP	THERAHOONEY	VIMOVO	ZIOPTAN
SANDOSTATIN LAR DEPOT	TIKOSYN [^]	VISCO-3	ZIPSOR
SAVAYA	TIMOPTIC OCUDOSE	VIVELLE-DOT [^]	ZOCOR [^]
SEBUDERM	TIVORBEX	VIVLODEX	ZOLOFT [^]
SERNIVO	TOBI SOLUTION [^]	VOSEVI	ZOMACTON
SEROQUEL [^] , SEROQUEL XR [^]	TOLSURA	VYTORIN [^]	ZOMIG TABLETS [^] , ZOMIG ZMT [^]
SIGNIFOR LAR	TOPAMAX [^]	WELLBUTRIN SR [^]	ZONEGRAN [^]
SIKLOS	TOPICORT SPRAY	XADAGO	ZORVOLEX
SILVASORB	TOPIRAMATE ER CAPSULES	XALATAN [^]	ZURAMPIC
SINGULAIR [^]	TREXIMET [^]	XANAX [^] , XANAX XR [^]	ZYCLARA
SITAVIG	TRIBENZOR [^]	XATMEP	ZYFLO CR [^]
SOFOSBUVIR, VELPATASVIR	TRICOR [^]	XELPROS	ZYTIGA 250 MG [^]
SONAFINE	TRILEPTAL [^]	XENAZINE [^]	
SOVALDI	TRIVIDIA (TRUETEST, TRUETRACK)	XOLEGEL DUO, KIT	
SPIRIVA HANDIHALER, SPIRIVA RESPIMAT	TRIVISC	XOPENEX HFA	
SPRAVATO	TUDORZA PRESSAIR	XPOVIO	

[^] Multisource brand exclusion – The generic equivalent of this brand-name medication is covered under your plan. FDA-approved generic medications meet strict standards and contain the same active ingredients as their corresponding brand-name medications, although they may have a different appearance. As new generic medications become available, additional multisource brand products may become excluded.